Business Of Biotech Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright
7 snips
Oct 28, 2024 Bill Enright, CEO of Barinthus Biotherapeutics, has a track record of taking on leadership roles during tumultuous times. He recounts how he turned around challenges at Altimmune during the 2008 financial crisis. Joining Barinthus before the COVID-19 pandemic, he made pivotal decisions that laid the foundation for future success. The conversation dives into innovations in immunotherapy targeting hepatitis B and celiac disease, as well as the importance of recognizing strategic opportunities in the ever-evolving biotech landscape.
AI Snips
Chapters
Transcript
Episode notes
Altimmune's Lehman Brothers Crisis
- Bill Enright joined Altimmune in June 2008, right before the Lehman Brothers collapse.
- He navigated the crisis by restructuring, taking no salary, and securing a BARDA contract for an anthrax vaccine.
Be Opportunistic and Persevere
- Embrace opportunistic career moves and don't be afraid to take chances.
- Perseverance is key, especially during challenging times.
Summer Without Salary
- Enright's team at Altimmune went without salary for a summer during the financial crisis.
- They persevered due to their trust in his leadership and the company's vision.